#BEGIN_DRUGCARD DB00410

# AHFS_Codes:
84:04.04

# ATC_Codes:
D06AX09
R01AX06

# Absorption:
No measurable systemic absorption

# Biotransformation:
Hepatic. Following intravenous or oral administration, mupirocin is rapidly metabolized. The principal metabolite is monic acid, which has no antibacterial activity.

# Brand_Mixtures:
Not Available

# Brand_Names:
Bactoderm
Bactroban
Bactroban Nasal
Centany
Turixin

# CAS_Registry_Number:
12650-69-0

# ChEBI_ID:
Not Available

# Chemical_Formula:
C26H44O9

# Chemical_IUPAC_Name:
9-{[(2E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-{[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl}oxan-2-yl]-3-methylbut-2-enoyl]oxy}nonanoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2239757

# Description:
Mupirocin (pseudomonic acid A, or Bactroban or Centany) is an antibiotic originally isolated from Pseudomonas fluorescens. It is used topically, and is primarily effective against Gram-positive bacteria. Mupirocin is bacteriostatic at low concentrations and bactericidal at high concentrations.
Mupirocin has a unique mechanism of action, which is selective binding to bacterial isoleucyl-tRNA synthetase, which halts the incorporation of isoleucine into bacterial proteins. Because this mechanism of action is not shared with any other antibiotic, mupirocin has few problems of antibiotic cross-resistance.

# Dosage_Forms:
Cream	Topical
Ointment	Topical

# Drug_Category:
Anti-Bacterial Agents
Antibiotics
Protein Synthesis Inhibitors

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Mupirocin

# HET_ID:
MRC

# Half_Life:
20 to 40 minutes

# InChI_Identifier:
InChI=1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1

# InChI_Key:
InChIKey=MINDHVHHQZYEEK-HBBNESRFSA-N

# Indication:
For the treatment of <i>Staphylococci</i> nasal carriers.

# KEGG_Compound_ID:
C11758

# KEGG_Drug_ID:
D01076

# LIMS_Drug_ID:
410

# Mechanism_Of_Action:
Mupirocin reversibly binds to bacterial isoleucyl-tRNA synthetase, an enzyme which promotes the conversion of isoleucine and tRNA to isoleucyl-tRNA. Prevention of this enzymes from functioning properly  results in the inhibition of bacterial protein and RNA synthesis.

# Melting_Point:
77-78 Â°C

# Molecular_Weight_Avg:
500.6222

# Molecular_Weight_Mono:
500.298533006

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164764568

# Pharmacology:
Mupirocin, an antibiotic produced from <i>Pseudomonas fluorescens</i>, is structurally unrelated to any other topical or systemic antibiotics. Mupirocin is used to treat infection caused by <i>Staphylococcus aureus</i> and beta-hemolytic streptococci including <i>Streptococcus pyogenes</i>. This antibiotic has little, if any, potential for cross-resistance with other antibiotics.

# Predicted_LogP_Hydrophobicity:
2.25

# Predicted_LogS:
-4.3

# Predicted_Water_Solubility:
2.65e-02 g/l

# Primary_Accession_No:
DB00410

# Protein_Binding:
97%

# PubChem_Compound_ID:
446596

# PubChem_Substance_ID:
46505594

# RxList_Link:
http://www.rxlist.com/cgi/generic/mupi.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00162

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
MRC
Mupirocine
Pseudomonic acid

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:19 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Mupirocin

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10212417	Thomas DG, Wilson JM, Day MJ, Russell AD: Mupirocin resistance in staphylococci: development and transfer of isoleucyl-tRNA synthetase-mediated resistance in vitro. J Appl Microbiol. 1999 Apr;86(4):715-22.
10821672	Brown MJ, Mensah LM, Doyle ML, Broom NJ, Osbourne N, Forrest AK, Richardson CM, O'Hanlon PJ, Pope AJ: Rational design of femtomolar inhibitors of isoleucyl tRNA synthetase from a binding model for pseudomonic acid-A. Biochemistry. 2000 May 23;39(20):6003-11.
11796355	Antonio M, McFerran N, Pallen MJ: Mutations affecting the Rossman fold of isoleucyl-tRNA synthetase are correlated with low-level mupirocin resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2002 Feb;46(2):438-42.
14657089	Hurdle JG, O'Neill AJ, Chopra I: The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide-intermediate Staphylococcus aureus is not associated with a significant fitness burden. J Antimicrob Chemother. 2004 Jan;53(1):102-4. Epub 2003 Dec 4.
20190824	Thomas CM, Hothersall J, Willis CL, Simpson TJ: Resistance to and synthesis of the antibiotic mupirocin. Nat Rev Microbiol. 2010 Apr;8(4):281-9. Epub 2010 Mar 1.
2496983	Rechsteiner T, Leisinger T: Purification of isoleucyl-tRNA synthetase from Methanobacterium thermoautotrophicum by pseudomonic acid affinity chromatography. Eur J Biochem. 1989 Apr 15;181(1):41-6.
365175	Hughes J, Mellows G: Inhibition of isoleucyl-transfer ribonucleic acid synthetase in Escherichia coli by pseudomonic acid. Biochem J. 1978 Oct 15;176(1):305-18.
659331	Hughes J, Mellows G: On the mode of action of pseudomonic acid: inhibition of protein synthesis in Staphylococcus aureus. J Antibiot (Tokyo). 1978 Apr;31(4):330-5.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X74219

# Drug_Target_1_GenBank_ID_Protein:
437916

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
ileS

# Drug_Target_1_Gene_Sequence:
>2754 bp
ATGGATTACAAAGAAACGTTATTAATGCCTAAAACAGATTTCCCAATGCGAGGTGGTTTA
CCAAACAAGGAACCGCAAATTCAAGAAAAATGGGATGCAGAAGATCAATACCATAAAGCG
TTAGAAAAAAATAAAGGTAACGAAACATTCATTTTACATGATGGCCCACCATACGCGAAT
GGTAACTTACATATGGGACATGCCTTGAACAAAATTTTAAAAGACTTTATTGTACGTTAT
AAAACTATGCAAGGGTTCTATGCACCATACGTACCAGGTTGGGATACACATGGTTTGCCA
ATTGAACAAGCATTAACGAAAAAAGGTGTTGACCGTAAGAAAATGTCAACAGCTGAATTC
CGTGAGAAATGTAAAGAATTTGCTTTAGAACAAATTGAATTACAGAAAAAAGATTTTAGA
CGTTTAGGTGTTCGTGGTGACTTTAATGATCCATATATTACATTAAAACCTGAATACGAA
GCTGCACAAATTCGTATTTTTGGAGAAATGGCAGATAAAGGTTTAATTTATAAAGGTAAA
AAGCCAGTTTATTGGTCTCCTTCAAGTGAGTCTTCATTAGCAGAAGCAGAAATTGAATAT
CACGATAAACGTTCAGCATCAATTTACGTTGCATTTAACGTTAAAGATGACAAAGGTGTC
GTTGATGCAGATGCTAAATTTATTATCTGGACAACAACGCCATGGACAATTCCATCAAAT
GTTGCGATTACCGTTCATCCAGAATTAAAATACGGTCAATACAATGTAAATGGCGAAAAA
TATATTATTGCAGAAGCCTTATCTGACGCCGTAGCAGAAGCACTGGATTGGGATAAAGCA
TCAATCAAATTAGAAAAAGAATACACAGGTAAGGAATTGGAGTATGTTGTAGCACAACAT
CCATTCTTAGATAGAGAATCGTTAGTGATTAATGGTGATCATGTTACTACAGATGCTGGT
ACAGGTTGTGTACATACAGCACCAGGTCACGGGGAAGATGACTATATTGTTGGTCAAAAA
TATGAATTGCCAGTAATTAGTCCAATCGATGATAAAGGTGTATTTACTGAAGAAGGCGGC
CAATTTGAAGGAATGTTCTATGATAAAGCTAATAAAGCCGTTACTGATTTATTAACAGAA
AAAGGTGCACTATTAAAATTAGACTTTATTACACATAGCTATCCACACGACTGGAGAACA
AAAAAACCTGTAATTTTCCGTGCTACACCACAATGGTTTGCTTCAATCAGTAAAGTAAGA
CAAGATATTTTAGATGCAATCGAAAATACAAACTTCAAAGTAAATTGGGGTAAAACACGT
ATTTACAATATGGTTCGTGACCGTGGCGAATGGGTTATTTCTCGTCAACGTGTTTGGGGT
GTACCGTTACCAGTATTTTATGCTGAAAATGGCGAAATTATCATGACGAAAGAAACAGTG
AATCATGTTGCTGATTTATTTGCAGAACACGGTTCAAATATTTGGTTTGAAAGAGAAGCG
AAAGACTTACTACCAGAAGGATTTACACATCCAGGCAGCCCTAACGGTACATTTACTAAA
GAAACAGACATTATGGACGTTTGGTTTGATTCTGGTTCATCACACCGTGGCGTGTTGGAA
ACAAGACCGGAATTAAGTTTCCCAGCAGATATGTATTTAGAAGGTAGTGACCAATATCGT
GGTTGGTTCAACTCTTCTATTACAACTTCAGTTGCTACAAGAGGAGTATCACCTTATAAA
TTCTTACTTTCTCATGGTTTTGTTATGGACGGTGAAGGTAAGAAAATGAGTAAATCTTTA
GGTAATGTGATTGTACCTGACCAAGTGGTTAAACAAAAAGGTGCTGATATTGCGAGACTT
TGGGTAAGTAGTACGGACTATTTAGCTGATGTTAGAATTTCTGATGAAATTTTAAAACAA
ACATCTGATGTTTATCGTAAAATCAGAAATACATTAAGATTTATGTTAGGTAATATTAAT
GATTTCAATCCTGATACAGATAGCATTCCTGAATCAGAGTTATTAGAAGTTGATCGTTAC
TTGCTAAATCGTTTACGTGAATTTACTGCAAGTACGATTAACAACTATGAAAACTTTGAC
TACTTAAATATTTATCAAGAAGTTCAAAACTTTATCAATGTTGAGTTAAGTAATTTCTAT
TTGGATTACGGTAAAGATATTTTATATATTGAACAACGTGATTCTCATATCCGTCGTAGT
ATGCAAACAGTGTTATATCAAATTTTAGTTGATATGACGAAGTTGTTAGCACCAATCTTA
GTGCATACAGCTGAAGAAGTTTGGTCTCATACACCACATGTTAAAGAAGAAAGTGTTCAC
TTAGCAGACATGCCTAAAGTTGTAGAAGTAGATCAAGCTTTATTGGATAAATGGCGTACA
TTTATGAATTTACGTGATGATGTGAACCGTGCATTAGAAACTGCTCGTAATGAAAAAGTT
ATTGGTAAATCATTAGAAGCTAAAGTTACGATTGCTAGTAACGATAAATTTAATGCATCT
GAATTCTTAACTTCATTTGATGCATTACATCAATTATTTATCGTGTCACAAGTTAAAGTT
GTAGATAAGTTAGATGATCAGGCAACAGCTTATGAACATGGTGATATTGTCATCGAACAT
GCAGATGGTGAAAAATGTGAAAGATGTTGGAACTATTCAGAGGATCTTGGTGCTGTTGAT
GAATTGACGCATCTATGCCCACGATGCCAACAAGTTGTAAAATCACTTGTATAA

# Drug_Target_1_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_1_General_References:
10446055	Silvian LF, Wang J, Steitz TA: Insights into editing from an ile-tRNA synthetase structure with tRNAile and mupirocin. Science. 1999 Aug 13;285(5430):1074-7.
8163160	Chalker AF, Ward JM, Fosberry AP, Hodgson JE: Analysis and toxic overexpression in Escherichia coli of a staphylococcal gene encoding isoleucyl-tRNA synthetase. Gene. 1994 Apr 8;141(1):103-8.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
892

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
104885

# Drug_Target_1_Name:
Isoleucyl-tRNA synthetase

# Drug_Target_1_Number_of_Residues:
917

# Drug_Target_1_PDB_ID:
1QU2

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00133	tRNA-synt_1
PF06827	zf-FPG_IleRS
PF08264	Anticodon_1

# Drug_Target_1_Protein_Sequence:
>Isoleucyl-tRNA synthetase
MDYKETLLMPKTDFPMRGGLPNKEPQIQEKWDAEDQYHKALEKNKGNETFILHDGPPYAN
GNLHMGHALNKILKDFIVRYKTMQGFYAPYVPGWDTHGLPIEQALTKKGVDRKKMSTAEF
REKCKEFALEQIELQKKDFRRLGVRGDFNDPYITLKPEYEAAQIRIFGEMADKGLIYKGK
KPVYWSPSSESSLAEAEIEYHDKRSASIYVAFNVKDDKGVVDADAKFIIWTTTPWTIPSN
VAITVHPELKYGQYNVNGEKYIIAEALSDAVAEALDWDKASIKLEKEYTGKELEYVVAQH
PFLDRESLVINGDHVTTDAGTGCVHTAPGHGEDDYIVGQKYELPVISPIDDKGVFTEEGG
QFEGMFYDKANKAVTDLLTEKGALLKLDFITHSYPHDWRTKKPVIFRATPQWFASISKVR
QDILDAIENTNFKVNWGKTRIYNMVRDRGEWVISRQRVWGVPLPVFYAENGEIIMTKETV
NHVADLFAEHGSNIWFEREAKDLLPEGFTHPGSPNGTFTKETDIMDVWFDSGSSHRGVLE
TRPELSFPADMYLEGSDQYRGWFNSSITTSVATRGVSPYKFLLSHGFVMDGEGKKMSKSL
GNVIVPDQVVKQKGADIARLWVSSTDYLADVRISDEILKQTSDVYRKIRNTLRFMLGNIN
DFNPDTDSIPESELLEVDRYLLNRLREFTASTINNYENFDYLNIYQEVQNFINVELSNFY
LDYGKDILYIEQRDSHIRRSMQTVLYQILVDMTKLLAPILVHTAEEVWSHTPHVKEESVH
LADMPKVVEVDQALLDKWRTFMNLRDDVNRALETARNEKVIGKSLEAKVTIASNDKFNAS
EFLTSFDALHQLFIVSQVKVVDKLDDQATAYEHGDIVIEHADGEKCERCWNYSEDLGAVD
ELTHLCPRCQQVVKSLV

# Drug_Target_1_Reaction:
ATP + L-isoleucine + tRNAIle = AMP + diphosphate + L-isoleucyl-tRNAIle

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes the attachment of isoleucine to tRNA(Ile). As IleRS can inadvertently accommodate and process structurally similar amino acids such as valine, to avoid such errors it has two additional distinct tRNA(Ile)-dependent editing activities. One activity is designated as 'pretransfer' editing and involves the hydrolysis of activated Val-AMP. The other activity is designated 'posttransfer' editing and involves deacylation of mischarged Val-tRNA(Ile)

# Drug_Target_1_SwissProt_ID:
P41972

# Drug_Target_1_SwissProt_Name:
SYI1_STAAU

# Drug_Target_1_Synonyms:
EC 6.1.1.5
IleRS
Isoleucine--tRNA ligase

# Drug_Target_1_Theoretical_pI:
5.17

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB00410
